Kornimate/medical-research-clean huggingface dataset:
new techniques to reduce intra-operative bleeding during complex liver resection

Conditions: Surgical Blood Loss

Summary: this observational study introduced an new advanced bleeding control strategy during complex liver resection.this newly described "stepwise vascular control" technique was efficacious and feasible to control intra-operative bleeding in complex hepatectomy involving second hepatic hilum and retro-hepatic inferior vena cava.


Eligibility criteria:
inclusion criteria: * tumor size is more than 5cm in diameter; * these tumor were close to or were compressing main hepatic veins and rivc directly; * pugh-child grade is a or indocyanine green retention rate at 15min (icg15%) is less than 10% .
augmentation trial of prazosin for post-traumatic stress disorder (ptsd)

Conditions: Stress Disorders, Post-Traumatic; Combat Disorders; Sleep Disorders

Summary: the purpose of this study is to determine whether prazosin will: * reduce the incidence of nightmares and sleep disturbance * increase functioning and sense of well being in combat-trauma exposed operation iraqi freedom/operation enduring freedom (oif/oef) veterans.

this is a 15-week randomized parallel design, double-blind, placebo-controlled augmentation trial of prazosin to evaluate the efficacy and tolerability of prazosin augmentation in the treatment of ptsd trauma-related nightmares, sleep disturbance, global function and sense of well-being, and other clinical features and comorbidities of ptsd. participants will be 210 oif/oef soldiers and veterans who have suffered war zone trauma. participants will be randomized 1:1 to prazosin or placebo and all previous psychotropic medications and/or psychotherapy will be maintained constant. randomization will be stratified by site and use of an antidepressant.

Eligibility criteria:
inclusion criteria * age \>18 years; * clear evidence of exposure to one or more war zone trauma events sufficient to satisfy dsm-iv criterion a1 for diagnosis of ptsd; * dsm-iv diagnosis of ptsd derived from the caps; caps total score \>50; * caps recurrent distressing dreams item score \>5 (of maximum score of 8); * stable dose of non-exclusionary medications and psychotherapeutic treatment for at least 4 weeks prior to randomization; * good general medical health. * female participants must agree to use a reliable form of birth control during the study. exclusion criteria * psychiatric/behavioral - meets dsm-iv criteria for current schizophrenia, schizoaffective disorder, psychotic disorder, delirium, or any dsm-iv cognitive disorder; substance dependence disorder within 3 months or any current substance dependence; current cocaine or stimulant abuse; severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others. * medical - acute or unstable chronic medical illness, including unstable angina, recent myocardial infarction (within 6 months), congestive heart failure, preexisting hypotension or orthostatic hypotension, chronic renal or hepatic failure, pancreatitis, meniere's disease, benign positional vertigo; narcolepsy, or diagnosed sleep apnea; allergy or previous adverse reaction to prazosin or other alpha-1 antagonist.

Keywords: posttraumatic stress disorder ptsd nightmares prazosin sleep disturbance combat trauma
inuniv and working memory

Conditions: Attention Deficit Hyperactivity Disorder

Summary: minimum 24 subjects aged 8-12 with a diagnosis of adhd will be prescribed extended release guanfacine (intuniv) to assess impact, if any, on working memory. pre and post testing using a standardized battery of tests for effect on symptoms of adhd and working memory will be administered and assessed.


Eligibility criteria:
inclusion criteria: 1.meet dsm-iv criteria for adhd, combined, inattentive, or hyperactive/impulsive subtype, as evidenced by minimum score of 24 on the adhd-rs-iv at baseline * 2 outpatient status * 3. age 8-12 (inclusive) at baseline * 4. males or pre-menarchal females * 5. english-speaking parent and subject * 6. if on stimulant medication, has demonstrated sub-optimal response to treatment ad is willing to be washed out (discontinued) from stimulant * 7. intellectual capacity to provide assent, as deemed by the principal investigator * 8. no known cardiac history, including bradycardia, heart block, syncope or tachycardia * 9. no known history of hypotension or hypotension at baseline * 10. willing to provide informed consent/ assent per irb protocol exclusion criteria: * • 1.meet dsm-iv criteria for adhd, combined, inattentive, or hyperactive/impulsive subtype, as evidenced by minimum score of 24 on the adhd-rs-iv at baseline * 2 outpatient status * 3. age 8-12 (inclusive) at baseline * 4. males or pre-menarchal females * 5. english-speaking parent and subject * 6. if on stimulant medication, has demonstrated sub-optimal response to treatment ad is willing to be washed out (discontinued) from stimulant * 7. intellectual capacity to provide assent, as deemed by the principal investigator * 8. no known cardiac history, including bradycardia, heart block, syncope or or tachycardia * 9. no known history of hypotension or hypotension at baseline * 10. willing to provide informed consent/ assent per irb protocol 11. no history of hepatic or renal impairment

Keywords: adhd, working memory
a trial comparing the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in japanese subjects with type 2 diabetes mellitus.

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in asia. the aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in japanese subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * male or female japanese subjects, age at least 20 years at the time of signing informed consent * type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening * hba1c (glycosylated haemoglobin) 7.0-11.0 % (both inclusive) by central laboratory analysis, with the aim of a median of 8.3%. when approximately 50% of the randomised subjects have a hba1c above 8.3%, the remaining subjects randomised must have a hba1c below or equal to 8.3%; or when approximately 50% of the randomised subjects have a hba1c below or equal to 8.3%, the remaining subjects randomised must have a hba1c above 8.3% * body-mass index (bmi) above or equal to 20 kg/m\^2 * subjects on stable therapy with one oad (defined as unchanged medication and unchanged dose) for at least 60 days (metformin, a-gi, tzd, su, sglt2i or glinide) prior to screening according to approved japanese labelling exclusion criteria: * previous treatment with insulin (except for short-term treatment in connection with intercurrent illness including gestational diabetes) * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening * anticipated initiation or change in concomitant medications in excess of 14 days known to affect weight or glucose metabolism * impaired liver function, defined as alanine aminotransferase (alt) or aspartate aminotransferase (ast) equal to or above 2.5 times upper limit of normal * renal impairment estimated glomerular filtration rate (egfr) below 60ml/min/1.73m\^2 as per chronic kidney disease epidemiology collaboration (ckd-epi) * screening calcitonin equal to or above 50 ng/l * history of pancreatitis (acute or chronic) * personal or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia type 2 (men 2) * subjects presently classified as being in new york heart association (nyha) class iv
pilot study of efficacy of mechanical insufflation exsufflation in stroke

Conditions: Stroke; Dysphagia

Summary: stroke patients with dysphagia have restrictive lung dysfunction and impaired cough response. this pilot study was performed to determine if mechanical insufflation exsufflation (mie) therapy can help recover impaired cough function.

mechanical insufflation- exsufflation (mi-e) is an assisted coughing machine that has been proven to be very effective in preventing the deterioration of pulmonary function in patients with degenerative neuromuscular disorders. impaired airway clearance in stroke patients is associated with increased incidence of aspiration pneumonia. in this pilot study the investigators attempt to assess the efficacy of mi-e as part of a protocol for patients with dysphagia with impaired cough response.

Eligibility criteria:
inclusion criteria presence of neurogenic dysphagia presence of impaired cough function exclusion criteria episodes of acute pneumonia or diagnosis of pulmonary embolism at time of enrollment. previous history of chronic respiratory dysfunction or other systemic disorders that may impair respiratory function (ex,rheumatoid arthritis, chronic renal disorder, spinal cord injury) episodes of diaphragm weakness due to peripheral polyneuropathy or phrenic nerve injury concomitant diagnosis of myopathy, muscular dystrophy, or other neurodegenerative disorders. episodes of rib fracture within one year of enrollment. chronic alcoholism diagnosis of bullous emphysema diagnosis of chronic renal failure

Keywords: stroke, dysphagia, cough, mechanical insufflation exsufflation
claustrophobia and magnetic resonance imaging

Conditions: Claustrophobia

Summary: the objective of the study is to determine the ability of open magnetic resonance imaging (mri) scanners to reduce claustrophobic reactions, thereby enabling more examinations of severely anxious patients. the investigators hypothesize that anxiety-based claustrophobia that prevents mr examinations without sedation can be reduced using an open mr scanner design thereby improving clinical management of those patients.


Eligibility criteria:
inclusion criteria: * severely anxious patients with reported claustrophobia during mri or with the inability to undergo mr examinations on conventional scanners * clinical indication for mr imaging of the head, spine, or shoulder. exclusion criteria: * contraindication to mr imaging (shrapnells, pacemakers, certain unsafe implants) * age below 18 years

Keywords: claustrophobia magnetic resonance imaging mri anxiety open design severely anxious patients
molecularly redefining small bowel adenocarcinoma to accelerate precision patient care

Conditions: Small Bowel Adenocarcinoma

Summary: small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. the sbamol study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. this effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.

small bowel adenocarcinoma (sba), an orphan cancer, has annual diagnoses of 12,070 in the usa and 100 in denmark. despite its rarity, patient management should prioritize evidence-based care, but large trials are not feasible, leading to data scarcity and suboptimal care. as a result, sba is treated like colorectal cancer, yet its prognosis is worse, indicating this parallel approach is insufficient. the grasp on sbas molecular landscape is limited compared to prevalent cancers. scant mutational profiling studies, suggest sba is a heterogeneous disease where subsets resemble other gastrointestinal cancers. this underscores the potential for personalized treatments, including targeted therapies and immunotherapies. comprehensive molecular characterization, using dna, rna, and t-cell receptor characteristics, can provide much-needed strategic direction for patient care and future trials. capitalizing on this, the investigators propose a comprehensive molecular characterization aiming to develop consensus molecular subtypes that can direct future trials and sba therapeutic strategies. the investigators hypothesize that a consensus molecular profiling approach can identify subgroups of sba with distinct molecular, cellular, and histological characteristics, that will benefit from tailored treatment strategies using chemotherapy, targeted therapy, and immunotherapy. to explore this hypothesis, the investigators will: (wp1) perform molecular and immunological characterization of tumor tissues from sba patients (n=200) to establish consensus molecular subtypes of sba and define their biological attributes; (wp2) ascertain therapeutic avenues tailored to each subtype and devise a molecular algorithm to prospectively categorize individual tumors in real-time, laying the groundwork for molecularly-driven management.

Eligibility criteria:
inclusion criteria: patients with histologically verified small bowel adenocarcinoma patients older than 18 years exclusion criteria: insufficient material for molecular testing patients registered in vævsanvendelsesregistret\& vævsanvendelsesregistret; refers to a central danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.

Keywords: small bowel adenocarcinoma messenger rna dna t-cell receptor sequencing
a study of avastin in combination with chemotherapy for treatment of colorectal cancer and non-small cell lung cancer (aries)

Conditions: Colorectal Cancer; Non-Small Cell Lung Cancer

Summary: this is an observational study designed to follow patients with metastatic or locally advanced and unresectable crc or locally advanced or metastatic nsclc (excluding predominant squamous histology) who are receiving avastin in combination with first-line chemotherapy. second-line metastatic crc patients are also eligible. patients who started their avastin containing therapy \<4 months prior to enrollment are eligible.


Eligibility criteria:
inclusion criteria: * signed informed consent form * metastatic or locally advanced and unresectable crc or locally advanced or metastatic nsclc (excluding predominant squamous histology) * eligible for avastin as a component of intended therapy * first-line chemotherapy (or second-line chemotherapy for crc) plus avastin initiated ≤ 4 months prior to study enrollment exclusion criteria: * any medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to provide informed consent or comply with the treatment and follow-up, as specified by the investigator * enrollment in a blinded, placebo-controlled bevacizumab trial

Keywords: nsclc avastin anti-vegf lung cancer colorectal cancer aries colon cancer
effect of hyaluronidase on intraocular pressure

Conditions: Intraocular Pressure Low

Summary: the aim of this study is to evaluate effect of retrobulbar local anaesthesia after addition of hyaluronidase on iop during cataract surgery


Eligibility criteria:
inclusion criteria: * 1-patients above the age of 50 years. 2-patients with age related cataract. 3-normal iop. exclusion criteria: * 1history of trauma. 2-patients with glaucoma. 3-previous ocular surgery. 4-patients with other ocular pathology. 5-uncontrolled diabetes or hypertension. 6-hypersensitivity to lignocaine. 7-uncooperative or epileptic patients.
endometrial scratching in couples with unexplained subfertility

Conditions: Subfertility

Summary: endometrial scratching in luteal phase of a spontaneous menstrual cycle may increase pregnancy rate in women with unexplained infertility.


Eligibility criteria:
inclusion criteria: * women aged between 20 and 39 years with at least one year of infertility * regular menstruation with the length of the cycle between 22-34 days and ovulation confirmed by appropriately timed mid-luteal progesterone * fertile semen variables * bilateral tubal patency (demonstrated by laparoscopy or hysterosalpingography).

Keywords: unexplained infertility-endometrial scratching effect of endometrial biopsy (scratching) on clinical pregnancy rates in women with unexplained infertility
from benchmark to surgical activity: the role of endobronchial fiducial markers for ground glass lung nodules resection.

Conditions: Lung Cancer; Lung Non-Small Cell Carcinoma; Lung; Node

Summary: with the risen popularity of low-dose computed tomography (ldct) for lung cancer screening, many patients present with peripheral pulmonary ground-glass nodules (ggns) with a suspicious solid part. the appropriate diagnostic and management strategy for those lesions can be questionable. if malignancy is suspected, a surgical biopsy with the guidance of various localization methods available is recommended. each localization method has its advantages and disadvantages. therefore, it may not be possible to establish a gold standard for localizing indeterminate lung nodules since comparative clinical trials are lacking.

the management of pulmonary ground-glass nodules (ggns) may be different. if ggn is an incidental finding through ldct, the lesion should be followed according to the current guidelines. it is recommend a multidisciplinary team discussion to be initiated if a new solid component develops or the solid portion size grows on follow-up ct as the risk of malignancy is high. attempts to preoperatively biopsy solid components in part-solid ggns are often not feasible and not helpful in clinical settings. currently, if malignancy is suspected, a surgical biopsy with the guidance of various localization methods is recommended. if malignancy is confirmed, sub-lobar resection may provide an excellent oncologic outcome. the lungvision system is a novel augmented-fluoroscopy-based real-time navigation and guidance technology for bronchoscopy that can enable real-time visualization and localization of pulmonary nodules. in this study, all patients over the age of 18 will be enrolled in case of finding of lung ggns with the presence of a solid part inside\> = 6 mm or with a solid part even less than 6 mm but with an increase in size. these must be subject to surgical treatment for both diagnostic or therapeutic purposes. these nodules must have a bronchus sign inside. in these patients, a bronchoscopy under general anesthesia with oro-tracheal intubation with lungvision system and r-ebus will be performed to select the area to mark with fiducial marker. after fiducial marker placement, a ct scan will be performed to control the position of fiducial marker compared to the lesion. patients will subsequently undergo surgical treatment by using intraoperative ultrasonography to detect the position of fiducial marker in the completely deflated lung. the correct positioning of the fiducial marker compared to the lesion and the complete surgical excision of the target lesion will be evaluated on the surgical specimen.

Eligibility criteria:
inclusion criteria: * all patients over the age of 18; * lung ggns with the presence of a solid part inside \> = 6 mm or with a solid part even less than 6 mm but with an increase in size; * subjects evaluated for surgical treatment during multidisciplinary tumor board. exclusion criteria: * patients not eligible for surgery

Keywords: ultrasound marker fluoroscopy lung cancer bronchoscopy
physical activity of asthmatic children

Conditions: Physical Activity; Asthma; Child Development

Summary: physical activity is mandatory to the optimal development and health of children. the presence of asthmatic manifestations may influence the comportment of children and its family toward exercise and practice of sports. there no scientific argument to advice a reduction of physical activity in asthmatic children, but previous studies showed that physical activity is reduced in asthmatic children. the aim of this observational study is to evaluate the existing factors leading to this reduction of physical activity in asthmatic children and their families.

physical activity is mandatory to the optimal development and health of children. the presence of asthmatic manifestations may influence the behaviour of children and its family with a significant reduction of exercise and practice of sports. there no scientific argument to advice such a reduction of physical activity in asthmatic children. the aim of this observational study is to evaluate the existing factors leading to this reduction of physical activity in asthmatic children and their families. to evaluate the factors explaining this behaviour the investigator design an observational study, based on a questionnaire. the evaluation of the number of sujets to complete this study is 50 asthmatic children. the whole population will be considered as the same group. this study may be further completed by a comparative and new study including asthmatic and non-asthmatic children.

Eligibility criteria:
inclusion criteria: * asthmatic children coming for regular follow-up * good control of asthma exclusion criteria: * previous pathologies with significant impact on physical activity
evaluation of the efficacy and safety of solabegron tablets for treatment of overactive bladder in adult women

Conditions: Overactive Bladder

Summary: this is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets, compared to matched placebo, administered twice daily for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency, and predominantly urgency incontinence) for at least 6 months.


Eligibility criteria:
inclusion criteria: * adult female subjects 18 to 80 years of age, with a ≥ 6-month history of symptoms of overactive bladder including: frequency, urgency, and urgency urinary incontinence. subjects must provide written informed consent and either be of non-childbearing potential or of childbearing potential meeting specific criteria (e.g., negative pregnancy test, sexual inactivity, acceptable methods of birth control, and use of hormonal contraceptives). exclusion criteria: * subjects must have no history of pelvic or bladder disease, e.g., grade 3/4 uterine prolapse, urogenital malignancy within the past 2 years, surgery for stress incontinence or pelvic prolapse repair within the past 6 months, or bladder injections with botulinum toxin at any time. * diabetes insipidus or poorly controlled type 1 or type 2 diabetes mellitus * cardiac conditions: prior cardiovascular events or procedures within 6 months of screening; congestive heart failure; abnormal ecg findings, including ecg qt correction interval (qtc) \> 470 msec at the screening visit; systolic blood pressure ≥ 180 mmhg or diastolic blood pressure ≥100mmhg, or heart rate \> 100 beats per minute. * abnormal tests of liver function * history of prior infection due to hiv or hepatitis b or hepatitis c virus * allergy or hypersensitivity to solabegron or mirabegron * women of childbearing potential: breastfeeding, pregnant, or actively trying to become pregnant * participation in a trial of an investigational or marketed drug ≤ 30 days prior to the screening visit or in any clinical trial of an investigational drug that may affect urinary function within 3 months prior to screening visit. * inability to read, understand, or complete study-related materials.

Keywords: overactive bladder urinary conditions urgency urinary incontinence urgency micturitions